{"classes":[{"categories":[{"measurements":[{"comment":"upper limit of the confidence interval was not estimable due to an insufficient number of participants with events","groupId":"OG000","lowerLimit":"7.6","upperLimit":"NA","value":"17.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"}],"units":"Participants"}],"title":"Entire Population"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.7","upperLimit":"17.7","value":"7.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"title":"Cervical Cancer Cohort"},{"categories":[{"measurements":[{"comment":"insufficient number of participants with events","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"title":"Non Cervical Cohort"}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"}],"units":"Participants"}],"description":"Will be summarized using the method of Kaplan and Meier and Cox proportional hazards models.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients received 7 mg of MEDI0457 intramuscularly (weeks 1, 3, 7, 12, and every 8 weeks thereafter) and durvalumab 1500 mg intravenously every 4 weeks starting at week 4.","id":"OG000","title":"Treatment Group"}],"paramType":"MEDIAN","populationDescription":"The cervical cancer cohort had 12 participants. The non cervical cohort had 9 participants.","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Median Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}